Abstract
The Expert Panel for Cosmetic Ingredient Safety reviewed updated information that has become available since their original assessment from 1982, along with updated information regarding product types, and frequency and concentrations of use, and reaffirmed their original conclusion that Choleth-24 is safe for topical applications to humans in the practices of use and concentration as described in this report.
Keywords
The Expert Panel for Cosmetic Ingredient Safety first published the Final Report on the Safety Assessment of Choleth-24 as Used in Cosmetics in 1982. 1 The Expert Panel concluded that Choleth-24 is safe for topical applications to humans in the present practices of use and concentration, as stated in that report. Upon re-review, the Expert Panel reaffirmed the original conclusion, as published in 2005. 2
Frequency and Concentration of Use (2022; 2002) According to Likely Duration and Exposure and by Product Category.
*Because each ingredient may be used in cosmetics with multiple exposure types, the sum of all exposure types may not equal the sum of total uses.
**Likely duration and exposure is derived based on product category (see Use Categorization https://www.cir-safety.org/cir-findings).
ǂThis product category is no longer included in the VCRP.
NR, not reported.
aIt is possible these products are sprays, but it is not specified whether the reported uses are sprays.
bNot specified whether a spray or a powder, but it is possible the use can be as a spray or a powder; therefore, the information is captured in both categories.
In December 2022, an extensive search of the world’s literature was performed for studies dated 1998 forward, and no new toxicological data were found. However, it should be noted that Choleth-24 is an inactive ingredient in two FDA-approved drug formulations. 5
In summary, the Expert Panel reviewed 2022 frequency and concentration of use data and noted the lack of any new, available, relevant safety data. Considering this information, as well as the information provided in the original safety assessment and the prior re-review document, the Expert Panel reaffirmed the 1982 conclusion for Choleth-24.
Footnotes
Author Notes
Unpublished sources cited in this report are available from the Director, Cosmetic Ingredient Review, 1620 L Street, NW, Suite 1200, Washington, DC 20036, USA.
Author Contributions
The articles in this supplement were sponsored by the Cosmetic Ingredient Review.
Declaration of Conflicting Interest
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: The articles in this supplement were sponsored by the Cosmetic Ingredient Review.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The articles in this supplement were sponsored by the Cosmetic Ingredient Review. The Cosmetic Ingredient Review is financially supported by the Personal Care Products Council.
